Prostate-specific antigen nadir and cancer-specific mortality following hormonal therapy for prostate-specific antigen failure

Journal of Clinical Oncology

Volumn 23, Issue 27, 2005, Pages 6556-6560

  Stewart, Alexandra J ^a   Scher, Howard I ^a   Chen, Ming Hui ^a   McLeod, David G ^a   Carroll, Peter R ^a   Moul, Judd W ^a   D'Amico, Anthony V ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; ANTIANDROGEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; TUMOR MARKER;

ADULT; AGED; ANDROGEN THERAPY; ANTIGEN DETECTION; ARTICLE; CANCER MORTALITY; CONTROLLED STUDY; FOLLOW UP; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; BLOOD; COHORT ANALYSIS; EVALUATION; METHODOLOGY; MIDDLE AGED; MORTALITY; PREDICTION AND FORECASTING; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROSTATE TUMOR; PROSTATECTOMY; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SURVIVAL; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; COHORT STUDIES; EVALUATION STUDIES; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 27244458795     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.20.966     Document Type: Article

References (17)

1. Zeitman AL, Chung CS, Coen JJ, et al: 10-year outcome for men with localised prostate cancer treated with external radiotherapy: Results of a cohort study. J Urol 171:210-214, 2004
2. Han M, Partin AW, Zahurak M, et al: Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol 169:517-523, 2003
3. D'Amico AV, Moul JW, Carroll PR, et al: Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst 95:1376-1383, 2003
4. Kwak C, Jeong SJ, Park MS, et al: Prognostic significance of the nadir prostate specific antigen level after hormone therapy for prostate cancer. J Urol 168:995-1000, 2002
5. Shulman MJ, Benaim EA: The natural history of androgen independent prostate cancer. J Urol 172:141-145, 2004
6. Lubeck DP, Litwin MS, Henning JM, et al: The CaPSURE database: A methodology for clinical practice and research in prostate cancer: CaPSURE Research Panel-Cancer of the Prostate Strategic Urologic Research Endeavor. Urology 48:773-777, 1996
7. Sun L, Gancarczyk K, Paquette EL, et al: Introduction to the Department of Defense Center for Prostate Disease Research Multicenter National Prostate Cancer Database, and analysis of changes in the PSA-era. Urol Oncol 6:203-209, 2001
8. American Joint Committee on Cancer-Prostate, in Greene FL (ed): AJCC Cancer Staging Manual (6th ed). New York, NY, Springer, 2002, pp 309-316
9. American Society for Therapeutic Radiology and Oncology Consensus Panel: Consensus statement-Guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys 37: 1035-1041, 1997
10. Neter J, Kutner MH, Wasserman W, et al: Simultaneous inferences and other topics in regression analysis-1, in Applied Linear Regression Models. Homewood, IL, McGraw-Hill, 1983, pp 150-153
11. Pound CR, Partin AW, Eisenberger MA, et al: Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281:1591-1597, 1999
12. Gleave ME, Goldenberg SL, Chin JL, et al: Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: Biochemical and pathological effects. J Urol 166:500-506; discussion 506-507, 2001
13. Gaynor JJ, Feuer EJ, Tan CC, et al: On the use of cause-specific failure and conditional failure probabilities: Examples from clinical oncology data. J Am Stat Assoc 88:400-409, 1993
14. Eisenberger MA, Blumenstein BA, Crawford ED, et al: Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 339:1036-1042, 1998
15. Hussain M: PSA as an outcome marker in de novo metastatic prostate cancer. Presented at Am Soc Clin Oncol Prostate Cancer Symposium, Orlando, FL, February 17-19, 2005
16. Tannock IF, de Wit R, Berry WR, et al: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502-1512, 2004
17. Petrylak DP, Tangen CM, Hussain MHA, et al: Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351: 1513-1520, 2004